{
    "clinical_study": {
        "@rank": "50186", 
        "acronym": "TAO", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Subcutaneum injection of placebo once-weekly for 3 months"
            }, 
            {
                "arm_group_label": "exenatide", 
                "arm_group_type": "Active Comparator", 
                "description": "Subcutaneum injection of exenatide once-weekly for 3 months"
            }
        ], 
        "brief_summary": {
            "textblock": "To examine if 3 months of treatment with a GLP-1 (glucagon-like-peptide-1) analogue can\n      induce weight loss in obese, non-diabetic patients with a diagnosis within the schizophrenic\n      spectrum.\n\n      The investigators will also examine possible associations between GLP-1 treatment and\n      peripheral metabolic parameters such as change in body fat and HbA1c. Moreover, the GLP-1\n      analogue treatment will be associated with the effects/changes on cognition and subjective\n      quality of life. Possible cerebral effects (pro-cognitive) of the GLP-1 analogue treatment\n      will associated and correlated with changes in the brain, functional magnetic resonance\n      imaging (fMRI)."
        }, 
        "brief_title": "Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Obesity", 
            "Metabolic Syndrome X", 
            "Drug-induced Obesity", 
            "Schizophrenia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Obesity", 
                "Schizophrenia", 
                "Obesity, Morbid", 
                "Metabolic Syndrome X"
            ]
        }, 
        "detailed_description": {
            "textblock": "The primary endpoint is weight loss after 3 months of treatment with the GLP-1 analogue\n      exenatide (Bydureon\u00ae).\n\n      Secondary endpoints comprise both physiological/metabolic parameters and cognitive\n      measurements:\n\n        -  Metabolic endpoints include amongst others: changes in body fat (DEXA-scan) and changes\n           of the HbA1c(average blood glucose levels), cholesterol and triglycerides. Moreover\n           physiological effects will be examined eg possible effect on central/peripheral\n           bloodpressure and heart rate.\n\n        -  Cerebral endpoints will be investigated via functional magnetic resonance imaging\n           (fMRI); including potential neuroprotective effects of exenatide. The main focus is\n           potential hippocampal volume changes and potential changes in cerebral blood flow.\n           Functional MRI will provide this data and the images will be correlated to both\n           cognitive tests and questionnaires.\n\n        -  Cognitive endpoints comprise potential improvements in cognition with focus on specific\n           memory tests (BACS, DART and Rey's Complex Figure) and possible improvements in\n           subjective quality of life (questionnaires)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age: 18 - 65 years\n\n          -  Diagnosis of the schizophrenia spectrum (ICD-10: F20.x, F25.x)both   in-patients and\n             out-patients will be included\n\n          -  Current and unchanged treatment with at least one antipsychotic drug (FGA and/or SGA\n             and/or depot treatment)\n\n          -  BMI \u226530 kg/m2\n\n          -  HbA1c < 6,5 %\n\n        Exclusion Criteria:\n\n          -  Substance dependence (ICD-10: F1x.2 (apart from nicotine addiction F17.2))\n\n          -  Diabetes or HbA1c \u22656.5%\n\n          -  Contraindications to MRI (metal implants, pacemakers, severe    claustrophobia, \u2265150\n             kg (max. bed weight in the MRI scanner))\n\n          -  Previous head trauma with a loss of consciousness for more than 5 minutes\n\n          -  Pregnancy (screened by urine human chorionic gonadotropin (hCG),lactation   or no\n             acceptance to use effective contraception during the intervention period\n\n          -  Severe somatic disease, including inflammatory bowel disease and chronic ketoacidosis\n\n          -  Allergy to exenatide\n\n          -  Coercive measures according the Danish Law of Psychiatry\n\n          -  conditions that according to sponsor are not congruous with participation in the\n             study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01794429", 
            "org_study_id": "EudraCT nr: 2012-005404-17"
        }, 
        "intervention": [
            {
                "arm_group_label": "exenatide", 
                "description": "Subcutaneum injection of exenatide once-weekly for 3 months", 
                "intervention_name": "Exenatide", 
                "intervention_type": "Drug", 
                "other_name": "Bydureon"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Subcutaneum injection of placebo once-weekly for 3 months", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antipsychotic Agents", 
                "Exenatide"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Obesity", 
            "The Metabolic Syndrome/disturbances", 
            "Drug-induced adipositas", 
            "Schizophrenia", 
            "GLP-1 analogue", 
            "cerebral effects"
        ], 
        "lastchanged_date": "December 20, 2013", 
        "location": {
            "contact": {
                "email": "pelle@cnsr.dk", 
                "last_name": "Pelle L. Ish\u00f8y, MD", 
                "phone": "+45 2674 3184"
            }, 
            "contact_backup": {
                "email": "bebdrup@cnsr.dk", 
                "last_name": "Bj\u00f8rn H. Ebdrup, MD PhD", 
                "phone": "+45 2613 3832"
            }, 
            "facility": {
                "address": {
                    "city": "Glostrup", 
                    "country": "Denmark", 
                    "zip": "2600"
                }, 
                "name": "Cnsr/Cins"
            }, 
            "investigator": {
                "last_name": "Pelle L. Ish\u00f8y, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "2", 
        "official_title": "Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue", 
        "overall_contact": {
            "email": "pelle@cnsr.dk", 
            "last_name": "Pelle L Ish\u00f8y, MD", 
            "phone": "(0045) 2674 3184"
        }, 
        "overall_contact_backup": {
            "email": "bebdrup@cnsr.dk", 
            "last_name": "Bj\u00f8rn H Ebdrup, MD PhD", 
            "phone": "(0045) 2613 3832"
        }, 
        "overall_official": {
            "affiliation": "University of Copenhagen", 
            "last_name": "Pelle L Ish\u00f8y, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Denmark: National Board of Health", 
                "Denmark: The Regional Committee on Biomedical Research Ethics", 
                "Denmark: Danish Dataprotection Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint is weight loss after 3 months of treatment with a GLP-1 analogue.", 
            "measure": "Weight loss", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01794429"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Copenhagen", 
            "investigator_full_name": "Bjorn H. Ebdrup", 
            "investigator_title": "MD PHD", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "description": "The investigators will explore potential effects of GLP-1 analogue treatment on different peripheral metabolic parameters: mainly changes in body fat composition (measured by DEXA-scan) and effects on HbA1c, triglycerides and cholesterol.", 
            "measure": "Effects of GLP-1-analogue treatment on body fat composition", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "source": "University of Copenhagen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bjorn H. Ebdrup", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}